Clinical Trial Update: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations [Phase 3]

View source ↗

Summary

Phase III open-label first-line study evaluating Dato-DXd in combination with durvalumab and carboplatin for advanced non-small cell lung cancer without actiona…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Dato-DXd (datopotamab deruxtecan)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: NSCLC | Phase 3 | Status: ACTIVE_NOT_RECRUITING